Tumaini Trial Begins Vaccinating in DR Congo, Testing Whether Ervebo Protects Against Bundibugyo Ebola

In Bunia, the main city of Ituri province in the Democratic Republic of the Congo, the first volunteers in a new vaccine study have reportedly received their shots. Reports published October 24 said the vaccine given was Ervebo, which is licensed for Ebola disease caused by Zaire ebolavirus. The study, called Tumaini, is meant to answer a question that remains open: whether that vaccine can protect people against Bundibugyo virus disease.

Al Jazeera reported the launch, and MedicalXpress corroborated it in an AFP report. The launch is a research milestone in the middle of an active outbreak. It is not evidence that the vaccine works. No safety, immune-response or efficacy results from Tumaini have been released.

The question exists because Bundibugyo virus is distinct from Zaire ebolavirus, though both can cause Ebola disease. Protection against one cannot be assumed to extend to the other; it has to be shown in study results. In May, a World Health Organization expert review found that no vaccine or treatment had been specifically approved for Bundibugyo virus disease. It called the evidence that Ervebo might protect against the virus limited and inconclusive, and advised that such use be evaluated in carefully designed research. Tumaini, whose name means "hope" in Swahili, is that research. It is not a routine outbreak vaccination campaign.

The Coalition for Epidemic Preparedness Innovations, or CEPI, describes Tumaini as a pivotal Phase 2/3 adaptive platform trial. A platform can test more than one candidate under a shared framework as new vaccines become ready, rather than building a separate trial for each. Ervebo is expected to go first. CEPI said on October 13 that two vaccines tailored to Bundibugyo virus are in early-stage studies: an mRNA candidate from Moderna, and a ChAdOx1 candidate developed by the University of Oxford and the Serum Institute of India. Those could be added to Tumaini when available.

The trial uses ring vaccination, concentrating on contacts at high risk of infection, such as people exposed to a confirmed case and others closely connected to that exposure. CEPI says it will assess safety, immunogenicity (the body's immune response) and efficacy, meaning whether vaccination reduces disease among people at risk. Public descriptions, however, do not give a planned sample size, endpoint definitions, a statistical analysis plan, or the allocation and comparator arrangements. That makes it too early to say how quickly a reliable efficacy answer might emerge.

News reports say the trial will include pregnant women and children 12 and older, though detailed eligibility criteria have not been published. It is led by the Congolese Institut National de Recherche Biomédicale and the University of Antwerp's Global Health Institute, with the Congolese Ministry of Health as national lead. CEPI identifies the two research institutions as co-sponsors. WHO is giving strategic, technical and scientific advice but is not a sponsor.

Tumaini follows a separate study in the country that asks a different question. In July, WHO announced enrollment in PARTNERS, a randomized therapeutic trial for people already confirmed to have Bundibugyo virus disease, evaluating the experimental antibody treatment MBP134 and the antiviral remdesivir. PARTNERS looks at treatment after infection; Tumaini looks at prevention among people at heightened risk. A good result in one would not show that the other intervention works.

Outbreak totals have varied in public accounts this year, with different dates and case definitions. An active outbreak supplies the exposures needed to see whether a vaccine changes disease risk, but it can also complicate the work, since transmission patterns, access to affected communities and the pace of case detection all affect how much evidence accumulates. The Phase 2/3 label itself does not mean a vaccine works, and results will depend on the number and timing of infections observed.

The first vaccinations begin evidence gathering and do not change any vaccine's regulatory status for Bundibugyo virus disease. What to watch for next is safety and immune-response data, and whether the Moderna and Oxford/Serum Institute candidates join the platform.